{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 56,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/47",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.57,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Competitive landscape matrix showing Terminated vs Clinical programs",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "972f806a-0ec7-476d-9e2f-627531585b5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.36,
        "x": 0.61,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "MTD: maximum tolerated dose; monotx: monotherapy; HCQ: hydroxychloroquine; CoM: composition of matter patent; ORR: overall response rate; RR: response rate; EC: encorafenib + cetuximab; RP2D: recommended Phase 2 dose; FIH: First-in-Human",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57621d62-38a2-4066-a266-5180b37d5561",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.36,
        "x": 0.61,
        "y": 0.18
      },
      "kind": "list",
      "text": "Hit-and-run profile optimizing efficacy, tolerability; Safety and tolerability established; Encouraging signs of efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eac13366-61f8-4787-8d30-aa0283dd75a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "ERAS-007: Potential best-in-class ERK1/2 inhibitor in a field marked by attrition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86b525ca-836b-4c27-ae7e-7e95008e554c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "31b89106-e043-4ee9-b5a3-2459fad91512",
      "evidence": "diagram/other: Competitive landscape matrix showing Terminated vs Clinical programs",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "21636df4-bf7e-41ae-b4a9-a56aaed90a22",
      "evidence": "Contrasting terminated vs clinical programs to highlight competitive advantage",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}